

# Flora ENT



## Clinical Applications

- Promotes Oral Health\*
- Supports the Natural Immune Defenses of the Ears, Nose/ Nasopharynx, and Throat\*
- Supports Healthy Immune Function\*
- Naturally Promotes Fresh Breath\*

*Flora ENT is a chewable, strawberry-flavored probiotic formula that activates in the oral cavity for support of ear, nose, and throat health and to naturally promote fresh breath. As you chew, each tablet releases the DSM 13084 strain of *Streptococcus salivarius*, a beneficial bacterium that normally occurs in a healthy oral cavity. *S salivarius* adheres to cells in the cavity and positively affects the bacterial population and natural immune defenses therein. Once established, *S salivarius* DSM 13084 also naturally counteracts the production of volatile sulfur compounds that can cause bad breath.\**

All The 3rd Opinion Inc. Formulas Meet or Exceed cGMP Quality Standards

## Discussion

The oral cavity is home to a plethora of naturally occurring bacteria. Some of these microorganisms are an important aspect of maintaining good health and serve as a first line of defense. *Streptococcus salivarius* is one of the most numerous of these “good” bacteria found in the mouths of healthy individuals. It is becoming more evident that a healthy balance of bacteria in the mouth and promoting the presence of specific strains of certain bacteria in it may be important for throat, nasopharyngeal, and middle ear health.\*<sup>[1-4]</sup>

**Strain DSM 13084** *S salivarius* DSM 13084 (also known as ATCC BAA-1 024), found in Flora ENT was discovered and isolated by renowned microbiologist Professor John Tagg at the University of Otago in New Zealand. Spurred by his own experiences as a youth, he was determined to find a natural and proactive way to help support throat health, especially in children. Dr. Tagg followed New Zealand school children for many years, analyzing their saliva samples and looking for differences. A breakthrough came when Dr. Tagg and his team isolated the unique DSM 13084 strain of *S salivarius* from a healthy child who, over a six-year period, exhibited remarkable throat health. Work was then begun to develop this strain for use as an advanced probiotic in the wellness market. DSM 13084 is an extremely safe yet powerful strain that has been deposited in culture collections.\*<sup>[5-7]</sup>

DSM 13084 has been shown to adhere to cells of the oral cavity and populate therein.<sup>[4,8-10]</sup> Not only does this strain exert its benefits through the typical colonization or “power in numbers” method, but it also produces several bioactive peptides, including salivaricin A and salivaricin B, that support oral health.\*<sup>[4,8,11,12]</sup>

**Ear, Nose/Nasopharynx, and Throat Health** Flora ENT represents a new “bioprotic” approach; that is, using probiotics to enhance health in non-intestinal sites for specific applications.<sup>[8]</sup> DSM 13084 promotes healthy levels of beneficial oral microorganisms, and thereby supports upper respiratory health.<sup>[9]</sup> Studies suggest that children with naturally occurring *S salivarius* DSM 13084-like strains are better able to maintain healthy mouth and throat microbial populations. Preliminary studies performed in children and adults have shown that supplementation with DSM 13084 has a statistically significant impact on throat, tonsil, and middle ear health.<sup>[4,8]</sup> In addition, preliminary in vitro and animal data from a 2012 study suggest that DSM 13084 positively affects the presence of *Candida albicans* in the oral mucosa and may inhibit its attachment to denture acrylic resins.\*<sup>[13]</sup>

**Fresh Breath** The predominant microbiota on the tongue of subjects with and without bad breath differs.<sup>[14]</sup> When certain bacteria break down proteins on the tongue, volatile sulfur compounds (VSC) that cause bad breath are released. In a placebo-controlled trial, Burton et al showed that administration of the DSM 13084 strain in 13 subjects resulted in a substantial decrease in VSC levels compared to controls.<sup>[15]</sup> The introduction of DSM 13084 helps balance the microflora of the mouth because it competes with the sulfur-producing bacteria for space while leaving room for more good bacteria to flourish.<sup>[15-17]</sup> This method of supporting a microbial population that limits the activities of sulfur-producing bacteria gets to the source of bad breath.<sup>[15,16]</sup> Addressing bad breath at its source can provide longer-lasting results than methods that simply mask odors.\*

**For Best Results** Flora ENT tablets should be chewed slowly and thoroughly, ideally after the patient’s oral hygiene routines (e.g., brushing, flossing, rinsing). Waiting until the tablet is completely dissolved before swallowing is optimal. The tablets do not contain cariogenic sugars or other ingredients that could negatively affect dental health.

**\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.**



# Supplement Facts

Serving Size: 1 Tablet  
Servings Per Container: 30

	Amount Per Serving	%Daily Value
( <i>Streptococcus salivarius</i> DSM 13084)	1 Billion CFU† (10 mg)‡	**

\*\* Daily Value not established.

**Other Ingredients:** Xylitol, natural strawberry flavor (no MSG), ascorbyl palmitate, citric acid anhydrous, and silica.

†Colony-Forming Units

‡Formulated with 2 Billion CFU (20 mg) at time of manufacture

## Directions

As a maintenance dose, after your bedtime oral hygiene routine chew one tablet slowly and completely before swallowing. During periods of increased need, chew up to five tablets per day in divided dose for 90 days, or as directed by your healthcare professional.

Children and pregnant or lactating women should consult their healthcare practitioner prior to use. Do not use if foil is punctured.

## References

1. Marchisio P, Claut L, Rognoni A, et al. Differences in nasopharyngeal bacterial flora in children with nonsevere recurrent acute otitis media and chronic otitis media with effusion: implications for management. *Pediatr Infect Dis J.* 2003 Mar;22(3):262-68. [PMID: 12634589]
2. Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. *Trends Biotechnol.* 2003 May;21(5):217-23. [PMID: 12727383]
3. Wescombe PA, Hale JD, Heng NC, et al. Developing oral probiotics from *Streptococcus salivarius*. *Future Microbiol.* 2012 Dec;7(12):1355-71. [PMID: 23231486]
4. Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in preventing recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* and recurrent acute otitis media. *Int J Gen Med.* 2012;5:991-97. [PMID: 23233809]
5. Burton JP, Cowley S, Simon RR, et al. Evaluation of safety and human tolerance of the oral probiotic *Streptococcus salivarius* K12: a randomized, placebo-controlled, double-blind study. *Food Chem Toxicol.* 2011 Sep;49(9):2356-64. [PMID: 21722694]
6. Guglielmelli S, Taverniti V, Minuzzo M, et al. Oral bacteria as potential probiotics for the pharyngeal mucosa. *Appl Environ Microbiol.* 2010 Jun;76(12):3948-58. [PMID: 20418429]
7. Burton JP, Wescombe PA, Moore CJ, et al. Safety assessment of the oral cavity probiotic *Streptococcus salivarius* K12. *Appl Environ Microbiol.* 2006 Apr;72(4):3050-53. [PMID: 16598017]
8. Di Pierro F, Adami T, Rapacioli G, et al. Clinical evaluation of the oral probiotic *Streptococcus salivarius* K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by *Streptococcus pyogenes* in adults. *Expert Opin Biol Ther.* 2013 Mar;13(3):339-43. [PMID: 23286823]
9. Horz HP, Meinelt A, Houben B, et al. Distribution and persistence of probiotic *Streptococcus salivarius* K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. *Oral Microbiol Immunol.* 2007 Apr;22(2):126-30. [PMID: 17311636]
10. *Streptococcus salivarius* K12 colonisation - dose response. BLIS Technologies Ltd. June 9, 2009. Data on file.
11. Power DA, Burton JP, Chilcott CN, et al. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic *Streptococcus salivarius* K12. *Eur J Clin Microbiol Infect Dis.* 2008 Dec;27(12):1261-63. [PMID: 18560907]
12. Tagg JR. Prevention of streptococcal pharyngitis by anti-*Streptococcus pyogenes* bacteriocin-like inhibitory substances (BLIS) produced by *Streptococcus salivarius*. *Indian J Med Res.* 2004 May;119 Suppl:13-16. [PMID: 15232154]
13. Ishijima SA, Hayama K, Burton JP, et al. Effect of *Streptococcus salivarius* K12 on the in vitro growth of *Candida albicans* and its protective effect in an oral candidiasis model. *Appl Environ Microbiol.* 2012 Apr;78(7):2190-99. [PMID: 22267663]
14. Kazor CE, Mitchell PM, Lee AM, et al. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. *J Clin Microbiol.* 2003 Feb;41(2):558-63. [PMID: 12574246]
15. Burton JP, Chilcott CN, Moore CJ, et al. A preliminary study of the effect of probiotic *Streptococcus salivarius* K12 on oral malodour parameters. *J Appl Microbiol.* 2006 Apr;100(4):754-64. [PMID: 16553730]
16. Burton JP, Chilcott CN, Tagg JR. The rationale and potential for the reduction of oral malodour using *Streptococcus salivarius* probiotics. *Oral Dis.* 2005;11 Suppl 1:29-31. [PMID: 15752094]
17. Masdea L, Kulik EM, Hauser-Gerspach I, et al. Antimicrobial activity of *Streptococcus salivarius* K12 on bacteria involved in oral malodour. *Arch Oral Biol.* 2012 Aug;57(8):1041-47. [PMID: 22405584]

## Does Not Contain

Wheat, gluten, soy, animal or dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or preservatives.

**\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.**

